2nd Annual EVIDENCE 360: RWE, Pricing and Market Access Summit

Millennium Hotel and Conference Centre Gloucester, London, UK | 16–17 March 2026

The 2nd Annual EVIDENCE 360: RWE, Pricing & Market Access Summit is a two-day event focused on providing a dedicated platform for stakeholders across the UK and European healthcare ecosystem. The summit will explore the evolving role of Real-World Evidence (RWE) in shaping market access, pricing, and reimbursement strategies.

As healthcare faces increasing pressure to deliver cost-effective, evidence-based care, this event brings together thought leaders from pharma, biotech, regulators, payers, HTA bodies, and digital health. The summit will address the region’s most pressing challenges around access and pricing, offering valuable insights on overcoming barriers and advancing healthcare solutions.

Join leading experts to discuss how RWE can transform market strategies, drive decision-making, and ultimately improve patient outcomes. This summit offers a unique opportunity to collaborate, learn, and influence the future of healthcare access and pricing.

As healthcare systems across the UK and Europe continue to face mounting cost pressures and growing demands for value-based decision-making, Real-World Evidence (RWE) has emerged as a critical enabler of informed pricing, reimbursement, and market access strategies. Against this backdrop, the 2nd Annual EVIDENCE 360: RWE, Pricing and Market Access Summit, a leading Real-World Evidence conference 2026, will convene key stakeholders from across the healthcare ecosystem on 16–17 March 2026 in London.

This two-day summit is designed as a dedicated knowledge-sharing and collaboration platform for professionals navigating the evolving evidence landscape. The event brings together senior leaders from pharmaceutical and biotechnology companies, regulators, payers, health technology assessment (HTA) bodies, and digital health innovators to examine how real-world data and advanced analytics are reshaping access decisions across the UK and European markets.

Access More on 2nd Annual EVIDENCE 360: RWE, Pricing and Market Access Summit at https://realworldevidenceconference.com/upcoming-conferences/uk-edition/

Addressing the Changing Role of Real-World Evidence

With regulatory and reimbursement authorities increasingly relying on real-world insights to complement clinical trial data, the summit will focus on how RWE is being integrated into market access submissions, pricing negotiations, and post-launch evidence generation. Sessions will explore practical approaches to aligning evidence strategies with regional expectations while maintaining scientific rigor and transparency.

The agenda reflects the rapidly changing policy and regulatory environment, including the implementation of the EU HTA Regulation and Joint Clinical Assessments (JCA), as well as evolving NICE standards for RWE use in the UK. Participants will gain clarity on how these frameworks are influencing evidence requirements and decision timelines.

Why Attend

Attendees will benefit from a comprehensive program that combines strategic discussion with real-world application, including:

• In-depth case studies showcasing successful use of RWE in UK and European HTA submissions
• Strategic insights into region-specific pricing and reimbursement frameworks
• Regulatory updates on EU HTA policy developments, JCA implementation, and NICE guidance on RWE
• Exploration of emerging methodologies, including AI-driven analytics, digital endpoints, and patient-reported outcomes for evidence generation
• High-value networking opportunities with European regulators, payers, HTA experts, and market access leaders

Registration at https://realworldevidenceconference.com/upcoming-conferences/uk-edition/registration/

A Forum for Collaboration and Insight

The RWE EVIDENCE 360 Summit is more than just a conference—it serves as a dynamic forum for dialogue, collaboration, and forward-thinking strategy development. As a flagship Real-World Evidence (RWE) conference in 2026, it brings together a wide range of perspectives from across the healthcare value chain. The summit aims to drive more robust, data-driven decisions in pricing and market access by aligning evidence strategy with regulatory and payer expectations.

The summit provides a unique opportunity for industry leaders to collaborate on overcoming the complexities of market access and pricing. By fostering connections between pharma, biotech, regulators, payers, and HTA bodies, the event offers insights into how RWE can accelerate access, streamline reimbursement processes, and ultimately deliver sustainable value to patients and healthcare systems across the UK and Europe.

This event is a must-attend for those seeking to shape the future of healthcare access and strategy in a rapidly evolving landscape.